NASDAQ$ESPR
Esperion Therapeutics Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Esperion reported first quarter financial results, which included first-ever product sales revenue for NEXLETOL™ tablets, and provided company updates.
Esperion reported first quarter results with $1.8 million in total revenue, including $0.8 million from NEXLETOL sales and $1.0 million from collaboration revenue. The company had a net loss of $78.2 million, or $2.84 per share. They ended the quarter with $158.2 million in cash and expect an additional $150 million from Daiichi Sankyo Europe upon first commercial sale in the EU.
- Company secured marketing approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in Europe
- NEXLETOL™ (bempedoic acid) Tablets Commercially Available in the U.S. on March 30th
- NEXLIZET™ (bempedoic acid and ezetimibe) Tablets Commercially Available in the U.S. on June 4th
- Strong Capital Position with $158 Million in Cash and at Least $210 Million in Additional Collaboration Payments in 2020
Headline financials
Revenue & EPS history
Esperion · Revenue · Quarterly
$1.84M
Revenue by segment
Esperion · $1.8M total across 2 segments · Q1 2020
- Collaboration Revenue$1M—55.6%
- U.S. Net Product Revenue$800K—44.4%
Forward guidance
Esperion updated the full-year 2020 expense guidance. Research and development expenses for the full year 2020 are now expected to be $135 million to $145 million (previously $145 million to $155 million). Selling, general and administrative expenses for the full year 2020 are now expected to be $200 million to $210 million (previously $225 million to $235 million).
Tailwinds
- Expects an additional $150 million in cash proceeds from the Daiichi Sankyo Europe upon first commercial sale in the EU.
- Current cash resources, coupled with the expected future milestone payment under the Daiichi Sankyo Europe collaboration agreement of $150 million and NEXLETOL and NEXLIZET commercial net product sales are sufficient to fund continued operations through profitability.
- Any additional cash proceeds as a result from a ROW collaboration and the additional $50 million available to Esperion, at its option, under the Oberland Capital revenue-based funding agreement, are incremental to our path to profitably and further secures our sustainable cash runway.
- Research and development expenses for the full year 2020 are now expected to be $135 million to $145 million (previously $145 million to $155 million).
- Selling, general and administrative expenses for the full year 2020 are now expected to be $200 million to $210 million (previously $225 million to $235 million).
Headwinds
- Changes result from a natural slowing of incurred expenses due to changes in planned operating expenses due to the COVID-19 environment during the first and second quarter.
- Changes result from a natural slowing of incurred expenses due to adjustments to virtual launch programs, tools and marketing tactics versus office promotional activities.
- Esperion is not providing guidance for in 2020, EU royalties, or upfront and/or milestone payment(s) from a potential Rest-of-World (ROW) agreement.
- Esperion continues to expect $30 million in non-cash stock-based compensation.
- The effect of bempedoic acid on cardiovascular morbidity and mortality has not been determined.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
-2.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+0.9%
Avg return
30 days after
43%
19 / 44 earnings
Positive
+23.0%
Q3 2018
Best reaction
-47.6%
Q1 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -0.6% | -0.3% | |
| Q4 2025 | -11.5% | -19.7% | -28.3% | |
| Q3 2025 | -15.0% | +5.4% | +26.9% | |
| Q1 2025 | -7.7% | -23.8% | +10.5% | |
| Q4 2024 | +12.0% | +7.0% | -18.4% | |
| Q3 2024 | +3.2% | +10.0% | +57.5% | |
| Q2 2024 | -10.9% | -3.0% | -13.9% | |
| Q1 2024 | -3.8% | +3.3% | +16.5% | |
| Q4 2023 | -2.3% | -3.0% | +1.9% | |
| Q3 2023 | +3.7% | -5.2% | +64.6% | |
| Q2 2023 | +14.0% | +3.8% | +1.9% | |
| Q1 2023 | +8.1% | +14.1% | +0.0% | |
| Q4 2022 | -3.9% | +4.7% | -73.6% | |
| Q3 2022 | -1.1% | +5.3% | -14.6% | |
| Q2 2022 | +5.9% | +11.9% | +41.1% | |
| Q1 2022 | +11.3% | -3.8% | -1.9% | |
| Q4 2021 | +5.5% | +9.1% | +32.8% | |
| Q3 2021 | +5.3% | +2.3% | -11.3% | |
| Q2 2021 | -6.6% | -5.2% | -12.7% | |
| Q1 2021 | -25.1% | -16.5% | -20.7% | |
| Q4 2020 | -0.2% | -4.2% | -1.9% | |
| Q3 2020 | -19.3% | -15.7% | -0.8% | |
| Q2 2020 | -11.9% | -13.7% | -0.1% | |
| Q1 2020 | +8.8% | +19.1% | +11.9% | |
| Q4 2019 | -11.5% | -5.4% | -38.1% | |
| Q3 2019 | -8.0% | -5.2% | +22.4% | |
| Q2 2019 | -2.0% | -2.3% | -9.6% | |
| Q1 2019 | +5.0% | +0.3% | +2.5% | |
| Q4 2018 | +1.2% | +0.7% | -14.1% | |
| Q3 2018 | +23.0% | +29.4% | +17.0% | |
| Q2 2018 | +3.2% | +4.2% | +10.6% | |
| Q1 2018 | -47.6% | -41.8% | -46.1% | |
| Q4 2017 | +1.2% | +5.3% | -6.1% | |
| Q3 2017 | -1.9% | +0.0% | +12.7% | |
| Q2 2017 | +11.9% | +9.2% | +10.4% | |
| Q3 2016 | -2.5% | -3.9% | +8.8% | |
| Q2 2016 | -1.0% | -2.2% | -4.2% | |
| Q1 2016 | -7.8% | — | — | |
| Q4 2015 | -3.4% | — | — | |
| Q3 2015 | -3.3% | — | — | |
| Q2 2015 | -2.6% | — | — | |
| Q1 2015 | +2.6% | — | — | |
| Q4 2014 | +1.6% | — | — | |
| Q3 2013 | -3.3% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro